Member Info for Barno61

Stay strong. I said 28p today. It hit that and retraced. We could be on for 50p tomorrow .

Still massively undervalued

28p

Wow what a bounce. 16.4p

Heading all the way to 28p

Crisms technology is the only hope and game in town for many people.

It should work extremely well as it targets the problem directly. They own the implanted drug as well so win win.

The main driver is the market potential here.

£1.7 Billion and lives saved .

Direct implanting of their drug into the tumour.

Massive massive potential.

31 May 2024

CRISM Therapeutics Corporation

(AIM:CRTX)

Admission to Trading and First Day of Dealings

CRISM Therapeutics Corporation ("CRISM" or the "Company"), previously called Amur Minerals Corporation, is pleased to announce that, in conjunction and simultaneously with the completion of the acquisition of the entire issued share capital and other securities of Extruded Pharmaceuticals Limited at 8:00 a.m. today, its ordinary shares will commence trading on AIM under the ticker CRTX, with ISIN VGG042401262 and SEDOL number BS60QF6.

CRISM Therapeutics Corporation is a UK-based pharmaceutical company which has developed an innovative drug delivery technology, ChemoSeed, to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy. ChemoSeed is a polymer the size of a grain of rice, administering irinotecan, a generic drug approved to treat brain cancer and can be implanted directly into a tumour or the resection margin following the removal of a tumour. ChemoSeed will initially be used to treat high grade gliomas, a brain tumour with no satisfactory treatment.

More information on CRISM Therapeutics Corporation and the Admission Document can be found here: www.crismtherapeutics.com.

The Directors of CRISM consider key strengths to include:

· Potential for rapid progression to clinical trials, assuming no need for further toxicology trials, which would reduce time to conditional marketing authorisation by six to nine months and direct costs of development by £400,000

· Based on available animal data, the Tessa Jowell BRAIN MATRIX Scientific Advisory Board has approved the inclusion of ChemoSeed in its Phase II platform clinical trial, which represents an efficient and cost-effective opportunity for clinical development

· Utilising pre-approved drug, irinotecan, reduces risk profile in clinical trials

· Attractive end market with the high grade glioma market valued at circa £1.7 billion

· Target market has orphan disease designation, meaning that ChemoSeed could receive conditional marketing authorisation for high grade glioma in the UK following positive Phase II clinical trials

· CRISM expects to begin its first clinical trial in late 2025. Should the trial generate positive results, given the unmet need for new treatments, this may enable CRISM to commercialise the product for both sales of ChemoSeed and licensing of the platform technology

· If ChemoSeed works well in clinical trials, the Board anticipates ChemoSeed may get approval for compassionate use for other solid tumours where surgical resection takes place or there is ease of access to the tumour, such as pancreatic cancer

·

This is the banker drug they have :-

https://en.m.wikipedia.org/wiki/Irinotecan#:~:text=Irinotecan%2C%20sold%20under%20the%20brand,It%20is%20given%20intravenously.

What makes this a banker share is the following.

Crism Therapeutics Corp - Pharmaceutical company headquartered in Surrey - Begins first day of trading on AIM. On Wednesday, Crism changed its name from Amur Minerals Corp, after purchasing Extruded Pharmaceuticals Ltd and exiting its mineral exploration business.

The company, now Crism, has created ChemoSeed, an innovate polymeric delivery system for chemotherapy. It expects to begin its first clinical trial in 2025. The company says Chemoseed's potential for quick progression to clinical trials would reduce development costs by EUR400,000.

Crism Chief Operating Officer Andrew Webb commented: "We believe Crism has an attractive risk profile owing to using an existing pre-approved drug, irinotecan, and we have a clear strategy for progressing ChemoSeed through development and to commercialisation."

28 p. It’s a more reasonable valuation.

Undervalued by a mile considering the potential to save lives and make a fortune at the same time.

Thats why the share price is on the rise.

Rarely do you get in at the entry point like how.

This will fly up ..

Small percentage margin now between buy and sell makes for far more trading and movement .

Very solid buy from here!

From X

This was bound to happen at #CPX today.

Some heavy selling by traders to free up funds to pile into #BLUEJAY #JAY yesterday AM for the day trade; now flying back into CAP-XX this morning.

SP is also being driven also by punters' realization that a discounted placing is very unlikely to be forthcoming anytime soon, given DR GC's board position now (coupled with his leading equity position).

Expecting further strong news flow in weeks ahead, and a break of recent highs.

x.com/MylesMcNulty/s…

122% upside and that was without the Helium and hydrogen.

Stay out and get a deckchair.

Then sit on your hands for a few weeks.

Not much will happen until the US bell tolls.

Standard holding pattern emerging.

On the move back up after the rout.

Can’t buy or sell except “At Best”. MM need your shares.

Expect a large spike up when they can’t get more.

20 million by 8.01

Do not have a stop loss on Bluejay over the next few days. The MM will destroy them.

Should be another large rise tomorrow

30% of the companies shares traded today alone.

We could see 2-300.% here over the coming days

With a market cap of just £8 mill and Helium one at £38 mill with a much smaller find and a harsher area to extract in. Seems very very cheap!